These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 28659588)
1. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Huan Y; Jiang Q; Li G; Bai G; Zhou T; Liu S; Li C; Liu Q; Sun S; Yang M; Guo N; Wang X; Wang S; Liu Y; Wang G; Huang H; Shen Z Sci Rep; 2017 Jun; 7(1):4351. PubMed ID: 28659588 [TBL] [Abstract][Full Text] [Related]
2. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141 [TBL] [Abstract][Full Text] [Related]
3. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus. Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163 [TBL] [Abstract][Full Text] [Related]
4. β-Cell Inactivation of Panaro BL; Flock GB; Campbell JE; Beaudry JL; Cao X; Drucker DJ Diabetes; 2017 Jun; 66(6):1626-1635. PubMed ID: 28254842 [TBL] [Abstract][Full Text] [Related]
5. Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes. Kim TH; Kim MK; Cheong YH; Chae YN; Lee Y; Ka SO; Jung IH; Shin CY; Bae EJ; Son MH Eur J Pharmacol; 2016 Jan; 771():65-76. PubMed ID: 26621343 [TBL] [Abstract][Full Text] [Related]
6. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Flock G; Baggio LL; Longuet C; Drucker DJ Diabetes; 2007 Dec; 56(12):3006-13. PubMed ID: 17717280 [TBL] [Abstract][Full Text] [Related]
7. A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice. Li Z; Fang J; Jiao R; Wei X; Ma Y; Liu X; Cheng P; Li T Biomed Pharmacother; 2017 May; 89():1467-1475. PubMed ID: 28376584 [TBL] [Abstract][Full Text] [Related]
8. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice. Oshima H; Yoshida S; Ohishi T; Matsui T; Tanaka H; Yonetoku Y; Shibasaki M; Uchiyama Y Life Sci; 2013 Feb; 92(2):167-73. PubMed ID: 23246743 [TBL] [Abstract][Full Text] [Related]
9. Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function. Morita A; Mukai E; Hiratsuka A; Takatani T; Iwanaga T; Lee EY; Miki T Endocrine; 2016 Mar; 51(3):429-39. PubMed ID: 26349938 [TBL] [Abstract][Full Text] [Related]
10. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119. Li G; Meng B; Yuan B; Huan Y; Zhou T; Jiang Q; Lei L; Sheng L; Wang W; Gong N; Lu Y; Ma C; Li Y; Shen Z; Huang H Eur J Med Chem; 2020 Feb; 188():112017. PubMed ID: 31926470 [TBL] [Abstract][Full Text] [Related]
11. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization. Shah P; Ardestani A; Dharmadhikari G; Laue S; Schumann DM; Kerr-Conte J; Pattou F; Klein T; Maedler K J Clin Endocrinol Metab; 2013 Jul; 98(7):E1163-72. PubMed ID: 23633194 [TBL] [Abstract][Full Text] [Related]
12. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Neumiller JJ J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361 [TBL] [Abstract][Full Text] [Related]
13. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Yoshida S; Ohishi T; Matsui T; Shibasaki M Biochem Biophys Res Commun; 2010 Sep; 400(3):437-41. PubMed ID: 20804735 [TBL] [Abstract][Full Text] [Related]
14. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753 [TBL] [Abstract][Full Text] [Related]
15. Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors. Zhang Y; Wu M; Htun W; Dong EW; Mauvais-Jarvis F; Fonseca VA; Wu H Sci Rep; 2017 Aug; 7(1):7964. PubMed ID: 28801559 [TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells. Pugazhenthi S; Qin L; Bouchard R Eur J Pharmacol; 2015 May; 755():42-9. PubMed ID: 25720341 [TBL] [Abstract][Full Text] [Related]
17. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847 [TBL] [Abstract][Full Text] [Related]
18. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089 [TBL] [Abstract][Full Text] [Related]
19. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function. Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M Diabetes Obes Metab; 2011 Jan; 13(1):34-41. PubMed ID: 21114601 [TBL] [Abstract][Full Text] [Related]
20. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]